Shares in VistaGen Therapeutics have plummeted after the company reported that its lead pherine nasal spray candidate failed the first of two phase 3 trials in social anxiety disorder (SAD ...

VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Vistagen (VTGN) announced results from an exploratory Phase 2A study of PH284 in cancer cachexia. PH284 is an investigational pherine nasal ...

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.66 per share a year ago.

Vistagen (VTGN) announced enrollment of the first subject in a repeat dose study of fasedienol, its investigational neuroactive pherine nasal ...

Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced positive results from an exploratory Phase 2A study ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ByInvesting.com • Sep 12, 2023 VistaGen Therapeutics and Fuji Enter Exclusive Negotiations for a Potential License to Develop and Commercialize Vistagen’s PH80 in Japan Vistagen (Nasdaq ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

This page features the latest news about the VistaGen Therapeutics stock. VTGN stock touches 52-week low at $2.38 amid market challenges VistaGen Therapeutics Inc (NASDAQ:VTGN) stock has reached a ...